IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer - European Medical Journal
×

Browse

IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer

|
Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides an update on IMAAGEN, a multicentre, open-label, single-arm, phase 2 trial evaluating the effect of abiraterone acetate plus prednisone on prostate specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer without radiographic evidence of metastatic disease.